Clinical Trials Browser

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04136912 2025-10-06

3-D Super Resolution Ultrasound Microvascular Imaging

Phase 2 Terminated

27 enrolled 12 charts

BreastHead & Neck

Breast Neoplasms, Thyroid Neoplasms

NCT04659603 2025-10-01

CARMEN-BT01

Phase 2 Terminated

50 enrolled 20 charts

BreastGastrointestinal

Breast Cancer Metastatic

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

6 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04191382 2025-09-18

AMEERA-4

Phase 2 Terminated

105 enrolled 16 charts

Breast

Breast Neoplasms

NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

Phase 2 Terminated

3 enrolled

Breast

HER2-positive Breast Cancer

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT01703754 2025-08-28

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

Phase 2 Terminated

12 enrolled 24 charts

Breast

Breast Neoplasms

NCT03862131 2025-07-29

PROACT

Phase 2 Terminated

49 enrolled 12 charts

BreastLymphoidOther hematologic neoplasmPlasma cellSarcomaThoracic

Breast Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Sarcoma, Neoplasms, Plasma Cell, Cardiotoxicity

NCT04227327 2025-07-29

HERMIONE-7

Phase 2 Terminated

31 enrolled

Breast

Advanced Breast Cancer

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

25 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04720729 2025-06-22

MONDRIAN

Phase 2 Terminated

160 enrolled

Breast

HER2-negative Metastatic Breast Cancer

NCT04251169 2025-06-03

TATEN

Phase 2 Terminated

20 enrolled 19 charts

Breast

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00538343 2025-05-29

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Phase 2 Terminated

14 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00195091 2025-05-16

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Phase 2 Terminated

16 enrolled 5 charts

Breast

Breast Neoplasms

NCT04965688 2025-04-10

SPOCK

Phase 2 Terminated

2 enrolled 4 charts

Breast

Breast Neoplasms

NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Phase 2 Terminated

54 enrolled 11 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05336721 2025-03-24

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Phase 2 Terminated

9 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT04440982 2025-01-15

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Phase 2 Terminated

98 enrolled

Breast

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast

Breast Neoplasms

NCT04675827 2024-12-04

Decrescendo

Phase 2 Terminated

139 enrolled

Breast

Breast Neoplasms

NCT04493333 2024-11-27

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

Phase 2 Terminated

8 enrolled 11 charts

Breast

Vaginal Atrophy

NCT02317783 2024-11-20

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

Phase 2 Terminated

15 enrolled 6 charts

Breast

Breast Neoplasms

NCT05457842 2024-11-20

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery

Phase 2 Terminated

1 enrolled 8 charts

BreastDermatologic

Breast Neoplasms, Melanoma

Clinical Trials

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

TRANSCENDER

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

VEnT

AMTEC IIT: Phase 2 Multiarm Study in TNBC

AMEERA-3

INTEGRAL

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

ELPIS

Olinvacimab With Pembrolizumab in Patients With mTNBC

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

ATRA

TrasTUCAN

BIS-Program

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

MK-2140-002

ELEVATE TNBC

PAVO

TNBC

3-D Super Resolution Ultrasound Microvascular Imaging

CARMEN-BT01

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

WI223281

AMEERA-4

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

PROACT

HERMIONE-7

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

DESTINY-Breast01

MONDRIAN

TATEN

PERSEVERE

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

SPOCK

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Decrescendo

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery